Madrigal Pharmaceuticals (MIL:1MDGL) ROA %: -30.56% (As of Mar. 2026)


MIL:1MDGL Madrigal Pharmaceuticals Inc MIL:1MDGL
8 GF Score
Price €416.00
! 4 Warning Signs
View Full Analysis

What is Madrigal Pharmaceuticals ROA %?

Madrigal Pharmaceuticals MIL:1MDGL 8 ROA % is -30.56% as of Mar. 2026. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 1,422 Biotechnology companies, Madrigal Pharmaceuticals ranks better than 54.78% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Madrigal Pharmaceuticals's annualized Net Income for the quarter that ended in Mar. 2026 was €-326.6 Mil. Madrigal Pharmaceuticals's average Total Assets over the quarter that ended in Mar. 2026 was €1,068.7 Mil. Therefore, Madrigal Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was -30.56%.

The historical rank and industry rank for Madrigal Pharmaceuticals's ROA % or its related term are showing as below:

MIL:1MDGL' s ROA % Range Over the Past 10 Years
Min: -126.94   Med: -55.43   Max: -9.68
Current: -26.4

During the past 13 years, Madrigal Pharmaceuticals's highest ROA % was -9.68%. The lowest was -126.94%. And the median was -55.43%.

MIL:1MDGL's ROA % is ranked better than
54.78% of 1422 companies
in the Biotechnology industry
Industry Median: -32.87 vs MIL:1MDGL: -26.40

Madrigal Pharmaceuticals  (MIL:1MDGL) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-326.592/1068.6635
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-326.592 / 1077.228)*(1077.228 / 1068.6635)
=Net Margin %*Asset Turnover
=-30.32 %*1.008
=-30.56 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Madrigal Pharmaceuticals ROA % Related Terms


Madrigal Pharmaceuticals ROA % Historical Data

* Premium members only.

The historical data trend for Madrigal Pharmaceuticals's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Madrigal Pharmaceuticals ROA % Chart

Madrigal Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -89.59 -95.46 -73.71 -56.22 -23.78

Madrigal Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.27 -16.27 -38.13 -17.89 -30.56

MIL:1MDGL vs BMRN, ARWR, AXSM: ROA % Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Madrigal Pharmaceuticals ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's ROA % distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's ROA % falls into.


MIL:1MDGL
8GF Score
Madrigal Pharmaceuticals Inc MIL:1MDGL
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Madrigal Pharmaceuticals ROA % Calculation

Madrigal Pharmaceuticals's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-246.195/( (995.346+1075.689)/ 2 )
=-246.195/1035.5175
=-23.78 %

Madrigal Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is calculated as:

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-326.592/( (1075.689+1061.638)/ 2 )
=-326.592/1068.6635
=-30.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -30.56% mean?
Madrigal Pharmaceuticals (MIL:1MDGL) has a ROA % of -30.56% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Madrigal Pharmaceuticals and its competitors. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #643 out of 1422 companies in the Biotechnology industry, placing it in the top 45.2%.
Is Madrigal Pharmaceuticals' ROA % too high?
Madrigal Pharmaceuticals' current ROA % is -30.56%. Based on the distribution chart, Madrigal Pharmaceuticals ranks #643 out of 1422 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' ROA % compare to BMRN and ARWR?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #643 out of 1422 companies for ROA %. This puts Madrigal Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current ROA % is -30.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current ROA % of -30.56%. The current ROA % is -30.56%. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current ROA % is -30.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Madrigal Pharmaceuticals Business Description

Other Exchanges MDGL:USA0JXI:UKYDO1:Germany
Address 200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score

Get the complete analysis for MIL:1MDGL

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€416.00
Price